A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer (Q44618419)
Jump to navigation
Jump to search
scientific article published on 3 September 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer |
scientific article published on 3 September 2012 |
Statements
1 reference
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer (English)
1 reference
William J Gradishar
1 reference
Virginia Kaklamani
1 reference
Tarini P Sahoo
1 reference
Dasappa Lokanatha
1 reference
Vinod Raina
1 reference
Shailesh Bondarde
1 reference
Minish Jain
1 reference
Sunhee Kwon Ro
1 reference
Nathalie A Lokker
1 reference
Lee Schwartzberg
1 reference
3 September 2012
1 reference
1 reference
49
1 reference
2
1 reference
312-322
1 reference
Identifiers
1 reference
1 reference